Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.